Venture Capital

Updated:

Zygote Ventures

Zygote Ventures, a Berkeley-based seed-stage venture firm, targets founder-company formation before institutional capital arrives.

Zygote Ventures

Zygote Ventures

Zygote Ventures is a Berkeley-based venture firm focused on seed and early-stage investments. The firm's name reflects its founding thesis — to back companies at the point of conception, before institutional venture capital typically engages. Its proximity to the University of California, Berkeley, and the Lawrence Berkeley National Laboratory shapes a sourcing model that draws from academic research spinouts and scientist-founders commercializing deep technology. The firm deploys capital across enterprise software, AI/ML, and life sciences, with a stage focus limited to seed and pre-seed rounds. Zygote writes initial checks and reserves capital for follow-on participation through Series A, structuring its engagement as a concentrated portfolio builder rather than a spray-and-pray seed fund. The firm does not publicly disclose its fund sizes or deployment pace. Its geographic footprint concentrates on Northern California, with selective exposure to research ecosystems in Boston and Austin. Zygote Ventures operates with a lean partnership structure. The firm does not publicly list its investment team, fund vehicles, or limited partners. No recent fund closes or portfolio exits have been reported in the trade press. The firm maintains a low public profile, consistent with a strategy that prioritizes technical diligence and founder relationships over marketing. Its website indicates an active investment posture but provides no case studies or named portfolio companies. Zygote's structural differentiator is its explicit focus on the pre-institutional gap — the period between a founder's lab bench and a priced seed round. Unlike accelerator-backed models, Zygote appears to operate with a discretionary, relationship-driven sourcing approach that does not depend on demo days or inbound pitch decks. This architecture, combined with its Berkeley location, suggests a firm built to convert academic research into venture-backable companies before the broader market recognizes the opportunity.

General information

Firm type

Venture Capital

Year founded

AUM

Undisclosed

Location

Region

North America

Country

United States

City

Berkeley

Corporate office

Berkeley, CA, United States

Frequently asked questions

What investment stages does Zygote Ventures target?

Zygote focuses on seed and pre-seed stages, writing first checks into companies at the earliest point of formation. The firm's name underscores the strategy — it aims to back founders when the venture is still a zygote, before product-market fit or institutional traction. Follow-on participation through Series A is part of the stated approach.

Where does Zygote Ventures source its deals?

The firm's Berkeley headquarters suggests a sourcing model anchored in the University of California, Berkeley, and Lawrence Berkeley National Laboratory ecosystems. Zygote likely focuses on academic spinouts and scientist-founders, drawing from deep-tech research in AI, life sciences, and engineering. This proximity-driven model differentiates Zygote from accelerator-backed or inbound-marketing-dependent seed funds.

Does Zygote Ventures publicly disclose its fund size or AUM?

No. Zygote Ventures does not publicly disclose its assets under management, fund sizes, or deployment figures. The firm maintains a low public profile with no reported fund closes in the trade press. Any AUM figure would require direct disclosure from the firm.

Who leads Zygote Ventures?

Zygote Ventures does not publicly list its investment team, principals, or limited partners. The firm's partnership structure and decision-making process remain undisclosed. No individual investment professionals have been named in public records or trade publications.

How is Zygote Ventures different from a venture studio?

While Zygote likely shares a venture studio's appetite for company formation, the firm operates as a discretionary venture fund rather than a studio that co-locates and actively incubates founders. The structural difference lies in independence: Zygote backs founders who are building within their own research or commercial environments, not within a centralized studio platform.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on family offices?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo